Freeline Therapeutics
UCL Royal Free Medical School
Pond Street
London
NW3 2QG,
United Kingdom
Tel: 44-0-20-7794-4227
Fax: 44-0-20-7611-2032
Website: http://www.freelinetx.com/
Email: contact@freelinetx.com
93 articles with Freeline Therapeutics
-
Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary
2/10/2023
Freeline Therapeutics Holdings plc announced the closing of the previously announced sale of its CMC-focused German subsidiary, Freeline Therapeutics GmbH, along with certain related intellectual property, to Ascend Gene and Cell Therapies Ltd., for $25 million, subject to purchase price adjustments.
-
Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy
1/19/2023
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the publication of preclinical proof-of-concept data for its gene therapy candidate for Fabry disease, FLT190, in the Nature journal Gene Therapy.
-
Freeline Reports December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 05, 2023
1/5/2023
Freeline Therapeutics Holdings plc announced that on December 30, 2022, the Company granted four newly hired employees non-statutory options to purchase an aggregate of 48,900 of the Company’s ordinary shares.
-
Freeline Receives Approval to Transfer to Nasdaq Capital Market - November 29, 2022
11/29/2022
Freeline Therapeutics Holdings plc announced that it received approval from the Nasdaq Stock Market LLC to transfer the listing of its American Depositary Shares representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market.
-
Freeline Reports Third Quarter 2022 Financial Results and Corporate Update
11/15/2022
Freeline Therapeutics Holdings plc reported financial results for the third quarter of 2022 and announced its decisions to sell its CMC-focused subsidiary in Germany to Ascend Gene and Cell Therapies Ltd., streamline its organization to increase efficiency and strengthen its financial position, and prioritize the development of FLT201 in Gaucher disease and FLT190 in Fabry disease.
-
Freeline to Present at the Stifel 2022 Healthcare Conference
11/9/2022
Freeline Therapeutics Holdings plc announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York.
-
Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 03, 2022
11/3/2022
Freeline Therapeutics Holdings plc announced that on October 31, 2022, the Company granted three newly hired employees non-statutory options to purchase an aggregate of 75,500 of the Company’s ordinary shares.
-
Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 05, 2022
10/5/2022
Freeline Therapeutics Holdings plc announced that on September 30, 2022, the Company granted five newly hired employees non-statutory options to purchase an aggregate of 416,850 of the Company’s ordinary shares.
-
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease
10/4/2022
Freeline Therapeutics Holdings plc announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1 clinical trial of FLT190 in Fabry disease, a debilitating inherited disorder that leads to progressive organ damage and can result in early death as a result of a harmful build-up of fat in cells due to an enzyme deficiency.
-
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/6/2022
Freeline Therapeutics Holdings plc announced that on August 31, 2022, the Company granted two newly hired employees non-statutory options to purchase an aggregate of 64,050 of the Company’s ordinary shares.
-
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 04, 2022
8/4/2022
Freeline Therapeutics Holdings plc announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole Jones and four other newly hired employees non-statutory options to purchase an aggregate of 240,000 and 35,250 of the Company’s ordinary shares, respectively.
-
Freeline Therapeutics' hemophilia B drug demonstrated the strong possibility that a single injection of FLT180a, an experimental gene therapy, can reduce or eliminate the need for weekly injections.
-
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
7/21/2022
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the New England Journal of Medicine (NEJM) published positive data that expand upon previously announced long-term follow-up data for up to 3.5 years from the Phase 1/2 dose-finding B-AMAZE trial of the company’s AAVS3 gene therapy candidate, FLT180a, for people with hemophilia B.
-
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
7/10/2022
Freeline Therapeutics Holdings plc announced the presentation of safety and initial efficacy data from the first cohort of the Phase 1/2 dose-confirmation B-LIEVE trial for FLT180a, the company’s AAVS3-based gene therapy candidate for people with hemophilia B, at the International Society on Thrombosis and Haemostasis Congress being held in London, July 9-13, 2022.
-
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2022
7/1/2022
Freeline Therapeutics Holdings plc announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to purchase 5,500 of the Company’s ordinary shares.
-
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
6/24/2022
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy candidate FLT180a at the International Society on Thrombosis and Haemostasis (ISTH) Congress to be held in London, July 9-13, 2022.
-
Genmab and AbbVie announce positive data in large b-cell lymphoma, Intra-Cellular's bipolar depression candidate hits the endpoint in Phase III and more.
-
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
6/14/2022
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it has begun dosing the second cohort in its Phase 1/2 B-LIEVE dose confirmation trial of FLT180a in people with hemophilia B.
-
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
6/3/2022
Freeline Therapeutics Holdings plc disclosed the receipt of a notice on May 31, 2022 from the Nasdaq Stock Market LLC that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s American Depositary Shares on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450.
-
Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 03, 2022
6/3/2022
Freeline Therapeutics Holdings plc announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul Schneider, and six other newly hired employees non-statutory options to purchase an aggregate of 270,000 and 191,850 of the Company’s ordinary shares, respectively.